Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709888 · ClinicalTrials.gov registry record
Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
A clinical trial, sponsored by Saint John's Cancer Institute.
- Completed
- Registry status
- 20
- Enrollment target
NCT03709888 is a clinical trial that has completed, run by Saint John's Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT03709888 has completed, sponsored by Saint John's Cancer Institute.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Study is designed to assess the efficacy and safety of memantine XR and pregabalin in reducing neuropathic pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) caused by prior treatment with any chemotherapy as measured by the Brief Pain Inventory- Short Form (BPI-SF). It will also determine the influence of these drugs on peripheral neuropathy-related functional status and quality of life (QOL) as measured by the EORTC QLQ-C30.
Interventions
- DRUG Memantine XR-pregabalin combination therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-07-09 |
| Est. Completion | 2021-04-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03709888
The ClinicalTrials.gov registry entry for NCT03709888 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint John's Cancer Institute, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Memantine XR-pregabalin combination therapy is the first listed.
NCT03709888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03709888 about?
NCT03709888 is a clinical study titled "Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy". Study is designed to assess the efficacy and safety of memantine XR and pregabalin in reducing neuropathic pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) caused by prior treatment with any chemotherapy as measured by the Brief Pain Inventory- Short Form (BPI-SF). It will als...
What is the current status of trial NCT03709888?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2016-07-09. Estimated completion is 2021-04-29.
What interventions are being tested in trial NCT03709888?
The interventions under investigation include: Memantine XR-pregabalin combination therapy (DRUG).
Who is sponsoring clinical trial NCT03709888?
This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.